Answers are grounded in this paper and cite their sources.
Melanocytic tumors with heavily pigmented epithelioid melanocytes were previously lumped into the category of pigmented epithelioid melanocytoma. More recently, it has been recognized that a subgroup of these lesions are the result of genomic fusions involving PRKCA and are distinct from the classic PRKAR1α inactivated pigmented epithelioid melanocytoma. This divergence allows for more precise classification and prognostication. Since this distinction has become apparent, there have been only a few series describing the morphologic and molecular features of genomically confirmed PRKCA fusion melanocytic tumors. Most of these cases have been either benign or of intermediate grade and have had an indolent clinical course—only very rare malignant variants have been described. Hence, there is an extreme paucity of literature regarding malignant variants of PRKCA fusion melanocytic tumors. In this study, we present a rare case of a malignant SLC11A2::PRKCA fusion melanocytic tumor with massive expansion of the subcutis and zones of tumor necrosis, measuring to an overall size of 5.5 centimeters. OncoScan microarray identified 18 distinct chromosomal copy number changes. This included losses of chromosomes 13 and 17p, resulting in haploinsufficiency of the tumor suppressor genes RB1 and TP53 , respectively, as well as gains at 8q involving MYC . DNA sequencing studies were negative for any additional mutations. This case illustrates a rare example of the clinical, morphologic, and molecular features of a malignant variant of a PRKCA fusion melanocytic tumor.
No takes yet. Share an insight, caveat, or question.
Gerami et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: